Table 2 The timing and kinds of preventive treatments in two consecutive episodes of cluster bouts (N = 14)
Characteristics | 1st GT-treated episode | 2nd GT-treated episode | 95% CI | P-value |
|---|---|---|---|---|
Total duration of cluster bout, days | 38.0 (25.3,65.8) | 37.5 (16.3,77.0) | [-19.6, 23.3] | 0.855 |
Time to GT from the onset of cluster bout, days | 24.0 (14.3,34.3) | 11.0 (5.0–26.5) | [-0.8, 15.8] | 0.071 |
Time to end of cluster bout following GT, days | 12.0 (2.5,48.3) | 17.5 (8.5–43.3) | [-17.5,14.9] | 0.867 |
Preventives before GT | ||||
Transitional preventives | 4 (28.6) | 0 (0.0) | 0.049† | |
Prednisolone | 4 (28.6) | 0 (0.0) | 0.049† | |
GONB | 3 (21.4) | 0 (0.0) | 0.111 | |
Conventional Preventives | 5 (35.7) | 2 (14.3) | 0.272 | |
Verapamil | 4 (28.6) | 2 (14.3) | 0.324† | |
Lithium | 1 (7.1) | 0 (0.0) | 0.500† | |
Topiramate | 3 (21.4) | 0 (0.0) | 0.111 | |
Additional preventives after GT | ||||
Transitional preventives | 4 (28.6) | 7 (50.0) | 0.220 | |
Prednisolone | 3 (21.4) | 5 (35.7) | 0.339† | |
GONB | 2 (14.3) | 5 (35.7) | 0.192† | |
Conventional Preventives | 8 (57.1) | 10 (71.4) | 0.336 | |
Verapamil | 7 (50.0) | 6 (42.9) | 0.500 | |
Lithium | 4 (28.6) | 2 (14.3) | 0.324† | |
Topiramate | 2 (14.3) | 2 (14.3) | 0.702† | |